Guided Therapeutics, Inc.
GTHP
$0.1088
$0.00888.80%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -96.88% | -- | -- | -72.73% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -96.88% | -- | -- | -72.73% | -- |
| Cost of Revenue | -81.25% | -- | -- | -77.78% | -79.75% |
| Gross Profit | -112.50% | -- | -- | -69.23% | 120.25% |
| SG&A Expenses | 220.91% | -18.18% | -70.14% | -63.60% | -139.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 340.77% | -9.95% | -57.71% | -57.80% | -123.44% |
| Operating Income | -310.07% | 9.95% | 56.48% | 57.41% | 126.81% |
| Income Before Tax | -68.91% | 3.40% | 54.46% | 53.74% | 78.64% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -68.91% | 3.40% | 54.46% | 53.74% | 78.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -68.91% | 3.40% | 54.46% | 53.74% | 78.64% |
| EBIT | -310.07% | 9.95% | 56.48% | 57.41% | 126.81% |
| EBITDA | -307.65% | 9.98% | 56.59% | 57.55% | 127.11% |
| EPS Basic | -28.09% | 12.95% | 57.14% | 58.88% | 77.00% |
| Normalized Basic EPS | -351.85% | 13.10% | 58.03% | 58.26% | 120.93% |
| EPS Diluted | -116.85% | 12.95% | 57.14% | 50.00% | 77.12% |
| Normalized Diluted EPS | -351.85% | 13.10% | 58.03% | 58.26% | 120.93% |
| Average Basic Shares Outstanding | 16.70% | 10.81% | 9.84% | 11.06% | 9.88% |
| Average Diluted Shares Outstanding | 16.70% | 10.81% | 9.84% | 11.06% | 9.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |